|
JP5836940B2
(ja)
|
2009-06-26 |
2015-12-24 |
ソリシメド・バイオファーマ・インコーポレーテッド |
ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
|
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
CN102892786B
(zh)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
|
CA2833636A1
(en)
*
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
MX2014001222A
(es)
*
|
2011-07-29 |
2014-09-15 |
Univ Pennsylvania |
Receptores coestimuladores de cambio.
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
RS61400B1
(sr)
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
|
CA2920539C
(en)
|
2013-08-08 |
2024-01-02 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
SI3030575T1
(sl)
|
2013-08-08 |
2018-11-30 |
Cytune Pharma |
Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
KR102524920B1
(ko)
|
2014-07-22 |
2023-04-25 |
아폴로믹스 인코포레이티드 |
항-pd-1 항체
|
|
SG10201901057UA
(en)
|
2014-08-05 |
2019-03-28 |
Cb Therapeutics Inc |
Anti-pd-l1 antibodies
|
|
PT3177644T
(pt)
*
|
2014-08-05 |
2021-01-13 |
MabQuest SA |
Reagentes imunológicos que se ligam a pd-1
|
|
US9982052B2
(en)
*
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
CA2964155A1
(en)
|
2014-10-10 |
2016-04-14 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonist with checkpoint inhibitors
|
|
CN107148279B
(zh)
|
2014-10-21 |
2021-09-03 |
赛生药品股份国际有限公司 |
用免疫刺激剂治疗癌症
|
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2016191283A2
(en)
*
|
2015-05-22 |
2016-12-01 |
University Of Houston System |
Enzymatic immunomodulation of solid tumors and user thereof
|
|
PT3310805T
(pt)
|
2015-06-19 |
2021-05-19 |
Kobold Sebastian |
Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
CA2991628C
(en)
|
2015-07-16 |
2020-04-07 |
Bioxcel Therapeutics, Inc. |
A novel approach for treatment of cancer using immunomodulation
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
WO2017021911A1
(en)
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
AU2016303550B2
(en)
|
2015-08-04 |
2019-06-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
EP3331919A1
(en)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
JP6869987B2
(ja)
|
2015-09-01 |
2021-05-12 |
アジェナス インコーポレイテッド |
抗ｐｄ−１抗体及びその使用方法
|
|
BR112018006237A2
(pt)
|
2015-09-29 |
2018-10-09 |
Celgene Corp |
proteínas de ligação a pd-1 e métodos de uso das mesmas
|
|
SI3356404T1
(sl)
|
2015-10-02 |
2021-11-30 |
F. Hoffmann-La Roche Ag |
Protitelesa proti PD1 in postopki uporabe
|
|
MA43028B1
(fr)
|
2015-10-02 |
2021-09-30 |
Hoffmann La Roche |
Anticorps bispécifiques pour pd1 et tim3
|
|
PL3368572T5
(pl)
|
2015-10-02 |
2026-07-20 |
Les Laboratoires Servier |
Przeciwciała anty-PD-1 oraz kompozycje
|
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
PT3370768T
(pt)
|
2015-11-03 |
2022-04-21 |
Janssen Biotech Inc |
Anticorpos que se ligam especificamente ao pd-1 e seus usos
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
ES2954153T3
(es)
|
2015-12-22 |
2023-11-20 |
Regeneron Pharma |
Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
|
|
PL3964529T3
(pl)
|
2016-01-22 |
2025-10-27 |
MabQuest SA |
Nieblokujące przeciwciała specyficzne względem pd1
|
|
BR112018068461A2
(pt)
|
2016-03-15 |
2019-01-22 |
Mersana Therapeutics Inc |
conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
|
|
MA44483A
(fr)
|
2016-03-24 |
2019-01-30 |
Millennium Pharm Inc |
Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
CN106008714B
(zh)
*
|
2016-05-24 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-1人源化单克隆抗体及其应用
|
|
CA3026151A1
(en)
*
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
CN110087680B
(zh)
|
2016-08-19 |
2024-03-19 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
|
EP3515944A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
|
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
CN107840887B
(zh)
*
|
2016-09-21 |
2022-03-25 |
基石药业（苏州）有限公司 |
一种新的pd-1单克隆抗体
|
|
WO2018069927A1
(en)
|
2016-10-10 |
2018-04-19 |
The National Institute for Biotechnology in the Negev Ltd. |
Non-cytotoxic modified cells and use thereof
|
|
CN110049777A
(zh)
|
2016-11-01 |
2019-07-23 |
安奈普泰斯生物有限公司 |
针对程序性死亡-1(pd-1)的抗体
|
|
WO2018083087A2
(en)
|
2016-11-02 |
2018-05-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Binding proteins
|
|
TWI780083B
(zh)
|
2016-11-18 |
2022-10-11 |
丹麥商賽門弗鎮公司 |
抗pd-1抗體及組成物
|
|
CN110177803A
(zh)
|
2016-11-22 |
2019-08-27 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重新编程的组合物和方法
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
EP3548069A1
(en)
|
2016-12-01 |
2019-10-09 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy
|
|
WO2018100535A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
CN110300599B
(zh)
|
2016-12-07 |
2024-07-02 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
PT3565844T
(pt)
|
2017-01-09 |
2023-05-02 |
Tesaro Inc |
Métodos de tratamento de cancro com anticorpos anti-pd-1
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
EP3582855A1
(en)
|
2017-02-15 |
2019-12-25 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體－藥物結合物之組合療法
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
CA3052532A1
(en)
|
2017-04-05 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
AU2018247916B2
(en)
|
2017-04-05 |
2025-04-24 |
Les Laboratoires Servier |
Combination therapies targeting PD-1, TIM-3, and LAG-3
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
US10995149B2
(en)
|
2017-06-05 |
2021-05-04 |
Janssen Biotech, Inc. |
Antibodies that specifically bind PD-1 and methods of use
|
|
JP2020522555A
(ja)
|
2017-06-09 |
2020-07-30 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
組み合わせ療法
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
KR20200037250A
(ko)
|
2017-07-06 |
2020-04-08 |
메뤼스 엔.페. |
세포에 의해 발현되는 생물학적 활성을 조절하는 항체
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
JP2021511793A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
|
|
TWI708787B
(zh)
*
|
2018-03-02 |
2020-11-01 |
美商美國禮來大藥廠 |
Pd-1促效劑抗體及其用途
|
|
WO2019195770A1
(en)
|
2018-04-06 |
2019-10-10 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-nrp2 antibodies
|
|
CA3100253A1
(en)
|
2018-05-14 |
2019-11-21 |
Immunocore Limited |
Bifunctional binding polypeptides
|
|
WO2019241730A2
(en)
|
2018-06-15 |
2019-12-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
|
AU2019312366B2
(en)
|
2018-07-26 |
2025-08-14 |
Atyr Pharma, Inc. |
Compositions and methods for treating NRP2-associated diseases
|
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
|
BR112021007517A2
(pt)
|
2018-10-22 |
2021-10-26 |
Glaxosmithkline Intellectual Property Development Limited |
Dosagem
|
|
CA3117050A1
(en)
|
2018-10-29 |
2020-05-07 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
CN113330310A
(zh)
|
2018-11-09 |
2021-08-31 |
皮埃里亚生物科学有限责任公司 |
用于测定肿瘤微环境组成的方法和组合物
|
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
|
US20220107320A1
(en)
|
2019-02-15 |
2022-04-07 |
Incelldx, Inc. |
Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
|
|
CN113811329B
(zh)
*
|
2019-04-19 |
2025-10-14 |
天科雅生物科技有限公司 |
抗pd-1抗体和其用途
|
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
US20220235132A1
(en)
*
|
2019-06-05 |
2022-07-28 |
Anaptysbio, Inc. |
Pd-1 agonist and method of using same
|
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
|
CA3143634A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
CN114630675A
(zh)
|
2019-06-18 |
2022-06-14 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合
|
|
JP6881658B2
(ja)
|
2019-07-05 |
2021-06-02 |
小野薬品工業株式会社 |
Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
CA3143636A1
(en)
|
2019-07-12 |
2021-01-21 |
Michael Lim |
Compositions and methods for treating cerebral vasospasm
|
|
WO2021025140A1
(ja)
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
CA3151022A1
(en)
|
2019-09-17 |
2021-03-25 |
Bial - R&D Investments, S.A. |
Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
|
|
CA3150700A1
(en)
|
2019-09-17 |
2021-03-25 |
Renato T. Skerlj |
IMIDAZOLE SUBSTITUTE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
CN114901652A
(zh)
|
2019-09-17 |
2022-08-12 |
比亚尔R&D投资股份公司 |
用于治疗医学病症的经取代的饱和和不饱和n-杂环甲酰胺及相关化合物
|
|
AU2020358854B2
(en)
|
2019-10-03 |
2026-08-13 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-NRP2 antibodies
|
|
CN115916818A
(zh)
|
2019-12-11 |
2023-04-04 |
库利南肿瘤股份有限公司 |
抗cd19抗体和多特异性结合蛋白
|
|
JP2023509359A
(ja)
|
2019-12-17 |
2023-03-08 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
鉄依存性細胞分解の誘導物質との併用抗癌療法
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
JP2023517011A
(ja)
|
2020-03-05 |
2023-04-21 |
ネオティーエックス セラピューティクス リミテッド |
免疫細胞を用いて癌を治療するための方法および組成物
|
|
JP2023521228A
(ja)
|
2020-04-14 |
2023-05-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
癌の併用療法
|
|
WO2021209356A1
(en)
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
EP4149632A1
(en)
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
CA3181776A1
(en)
*
|
2020-05-26 |
2021-12-02 |
Boehringer Ingelheim International Gmbh |
Anti-pd-1 antibodies
|
|
CN116096906A
(zh)
|
2020-06-29 |
2023-05-09 |
旗舰创业创新五公司 |
工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
|
|
EP4199947A4
(en)
|
2020-08-18 |
2024-10-16 |
Onchilles Pharma, Inc. |
Modified porcine pancreatic elastase proteins
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
PE20241732A1
(es)
|
2021-03-31 |
2024-08-19 |
Merus Nv |
Dominios de union a pd-1 novedosos
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
EP4353746A4
(en)
*
|
2021-06-11 |
2024-12-04 |
Guangdong Fapon Biopharma Inc. |
Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof
|
|
US20240316104A1
(en)
|
2021-06-29 |
2024-09-26 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
JP2024528217A
(ja)
|
2021-08-03 |
2024-07-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗体および使用方法
|
|
JP2024534265A
(ja)
|
2021-08-23 |
2024-09-18 |
イミュニタス セラピューティクス，インコーポレーテッド |
抗ｃｄ１６１抗体及びその使用
|
|
TW202440647A
(zh)
*
|
2021-11-19 |
2024-10-16 |
英商米羅比奧有限公司 |
經工程改造之pd-1抗體及其用途
|
|
CA3251059A1
(en)
|
2022-05-02 |
2023-11-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions, systems and methods for modulating a target gene
|
|
AR129560A1
(es)
|
2022-06-08 |
2024-09-04 |
Tidal Therapeutics Inc |
Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
|
|
JP2025528212A
(ja)
|
2022-08-18 |
2025-08-26 |
イムノコア リミテッド |
複数ドメイン結合性分子
|
|
TW202423994A
(zh)
|
2022-08-18 |
2024-06-16 |
英商英美偌科有限公司 |
多域結合分子
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
US20260234258A1
(en)
|
2022-10-20 |
2026-08-13 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
US12030945B2
(en)
|
2022-10-25 |
2024-07-09 |
Seismic Therapeutic, Inc. |
Variant IgG Fc polypeptides and uses thereof
|
|
EP4646433A1
(en)
|
2023-01-06 |
2025-11-12 |
Lassen Therapeutics, Inc. |
Anti-il-18bp antibodies
|
|
TW202430560A
(zh)
|
2023-01-06 |
2024-08-01 |
美商拉森醫療公司 |
抗ｉｌ－１８ｂｐ抗體
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
US20240294651A1
(en)
|
2023-01-30 |
2024-09-05 |
Kymab Limited |
Antibodies
|
|
GB202306345D0
(en)
|
2023-04-28 |
2023-06-14 |
Immunocore Ltd |
Binding molecules
|
|
WO2024233926A1
(en)
|
2023-05-10 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
WO2024243189A2
(en)
*
|
2023-05-22 |
2024-11-28 |
Board Of Regents, The University Of Texas System |
Antigen binding proteins targeting pd-1
|
|
GB202315181D0
(en)
|
2023-10-03 |
2023-11-15 |
Immunocore Ltd |
Peptide-HLA binding molecules
|
|
GB202320012D0
(en)
|
2023-12-22 |
2024-02-07 |
Immunocore Ltd |
Bispecific molecules
|
|
AU2025205814A1
(en)
|
2024-01-05 |
2026-07-09 |
Immunocore Limited |
Multi-domain molecules
|
|
TW202543581A
(zh)
|
2024-02-12 |
2025-11-16 |
美商艾伊拉醫療公司 |
遞送組成物
|
|
WO2025207705A1
(en)
|
2024-03-26 |
2025-10-02 |
Amgen Inc. |
Cancer treatments using mta-cooperative prmt5 inhibitors
|
|
TW202606706A
(zh)
|
2024-04-05 |
2026-02-16 |
美商安進公司 |
使用ｍｔａ協作的ｐｒｍｔ５抑制劑的胃腸癌治療
|
|
WO2025224084A1
(en)
|
2024-04-22 |
2025-10-30 |
Engimmune Therapeutics Ag |
Proteins comprising t cell receptor constant domains
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026072557A2
(en)
|
2024-09-24 |
2026-04-02 |
Genzyme Corporation |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
WO2026112559A1
(en)
|
2024-11-25 |
2026-05-28 |
Genzyme Corporation |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|